Patents by Inventor Hiroshi Inooka

Hiroshi Inooka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11089805
    Abstract: The present invention provides a mucosal immunomodulator comprising, as an active ingredient, at least one selected from the group consisting of compounds represented by the following formula (1), compounds represented by the following formula (2) and compounds represented by the following formula (3), and salts thereof.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: August 17, 2021
    Assignees: Yamada Bee Company, Inc., National University Corporation Kumamoto University
    Inventors: Shogo Misumi, Tomoki Ikuta, Tomoki Tatefuji, Hiroko Tani, Hiroshi Inooka
  • Publication number: 20190230967
    Abstract: The present invention provides a mucosal immunomodulator comprising, as an active ingredient, at least one selected from the group consisting of compounds represented by the following formula (1), compounds represented by the following formula (2) and compounds represented by the following formula (3), and salts thereof.
    Type: Application
    Filed: October 12, 2017
    Publication date: August 1, 2019
    Applicant: National Unversity Corporation Kumamoto University
    Inventors: Shogo MISUMI, Tomoki IKUTA, Tomoki TATEFUJI, Hiroko TANI, Hiroshi INOOKA
  • Patent number: 9175037
    Abstract: An object of the present invention is to provide a novel anorectic agent. Another object of the invention is to provide an NMU derivative which exhibits a high anorectic effect even when administered in a usual manner, for example, peripherally. These objects can be achieved by the compound represented by formula (I) or a salt thereof. In formula (I), Y represents a polypeptide containing an amino acid sequence set forth in SEQ ID NO.: 1 wherein 1 to 4 amino acids are substituted; X represents a methoxypolyethylene glycol; X? is absent or represents a methoxypolyethylene glycol; and a moiety represented by formula: La-Lb-[Lc]j represents a linker.
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: November 3, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Taiji Asami, Hiroshi Inooka, Naoki Nishizawa
  • Publication number: 20120094899
    Abstract: An object of the present invention is to provide a novel anorectic agent. Another object of the invention is to provide an NMU derivative which exhibits a high anorectic effect even when administered in a usual manner, for example, peripherally. These objects can be achieved by the compound represented by formula (I) or a salt thereof. In formula (I), Y represents a polypeptide containing an amino acid sequence set forth in SEQ ID NO.: 1 wherein 1 to 4 amino acids are substituted; X represents a methoxypolyethylene glycol; X? is absent or represents a methoxypolyethylene glycol; and a moiety represented by formula: La-Lb-[Lc]j represents a linker.
    Type: Application
    Filed: April 8, 2010
    Publication date: April 19, 2012
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Taiji Asami, Hiroshi Inooka, Naoki Nishizawa
  • Publication number: 20100286035
    Abstract: The objective of the present invention is to provide a new antifeedant. The other objective of the present invention is to provide a NMU derivative showing a high antifeedant activity even in common administration forms such as peripheral administration. A neuromedin U derivative wherein a methoxypolyethylene glycol is bound via a linker having a specific structure to a polypeptide which contains at least 8 amino acids of the C-terminus of an amino acid sequence of neuromedin U and which consists of the same or substantially the same amino acid sequence as the amino acid sequence of neuromedin U.
    Type: Application
    Filed: October 6, 2008
    Publication date: November 11, 2010
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tetsuya Ohtaki, Yasushi Masuda, Satoshi Kumano, Hiroshi Inooka
  • Publication number: 20100112601
    Abstract: The present invention provides an anti-PAC1 monoclonal antibody capable of recognizing a PAC1 having a native structure, a PAC1 activity regulator (in particular, activity inhibitor) containing the antibody, a prophylactic/therapeutic agent for a disease associated with accentuation of a bioactivity of PAC1, containing the antibody, a diagnostic reagent for a disease associated with an abnormality of PAC1 activity, containing the antibody, and a screening method for a substance that regulates the expression of PAC1, using the antibody and a PAC1-expressing cell.
    Type: Application
    Filed: August 7, 2007
    Publication date: May 6, 2010
    Applicants: Kyoto University, Takeda Pharmacetical Company Limited
    Inventors: Masahiro Shirakawa, Hiroshi Inooka
  • Publication number: 20070202099
    Abstract: The present invention provides an agent for improving the blood stability of an endogenous ligand, which comprises an antibody that has affinity to the mammalian endogenous ligand but substantially does not neutralize the same, and the above-described agent for the prophylaxis and/or treatment for a disease for which an increase in the blood concentration of the endogenous ligand and/or an prolonged blood half-life is prophylactically or therapeutically effective. Provided that the above-described agent is administered alone to a mammal without co-administering the same or substantially the same compound as the endogenous ligand, the blood stability of the endogenous ligand increases and the receptor activity-regulatory action thereof is enhanced.
    Type: Application
    Filed: March 29, 2005
    Publication date: August 30, 2007
    Inventors: Hiroshi Inooka, Nobuhiro Suzuki, Toshiro Kokubo, Tomofumi Kurokawa
  • Patent number: 6610655
    Abstract: Cyclic pentapeptides are disclosed having the following formula (I)-Cyclo(-A1-A2-A3-A4-A5-)-wherein A1, A2, A3, A4 and A5 are amino acid residues. The pentapeptide has amino acid residues in positions 1-2-3 to form a &ggr;-turn, and amino acid residues in positions 3-4-5-1 to form a &bgr;-turn in combination with the &ggr;-turn. D-&agr;-amino acid residues are selected for A1, A3, and A5 and L-&agr;-amino acid residues are selected for A2 and A4. Compounds having &ggr;-turns and &bgr;-turns can be synthesized, regardless of the kinds of amino acid residues, and it is possible to synthesize compounds in which desired amino acid residues are introduced into sites of &bgr;-turn and &ggr;-turn based on their importance from the viewpoint of biological activity. The present invention is therefore available for design of compounds having biological activity.
    Type: Grant
    Filed: November 15, 2001
    Date of Patent: August 26, 2003
    Assignee: Takeda Chemical Industries, Inc.
    Inventors: Mitsuhiro Wakimasu, Hiroshi Inooka, Satoshi Endo, Takashi Kikuchi
  • Publication number: 20020115823
    Abstract: Cyclic pentapeptides having a &ggr;-turn and a &bgr;-turn wherein the cyclic pentapeptide has the following formula (I);
    Type: Application
    Filed: November 15, 2001
    Publication date: August 22, 2002
    Inventors: Mitsuhiro Wakimasu, Hiroshi Inooka, Satoshi Endo, Takashi Kikuchi
  • Patent number: 6346604
    Abstract: Cyclic pentapeptides having a &ggr;-turn and a &bgr;-turn wherein the cyclic pentapeptide has the following formula (I): Cyclo(—A1—A2—A3—A4—A5—)  (I) wherein A1, A2, A3, A4 and A5 are amino acid residues; said pentapeptide having amino acid residues in positions 1-2-3 to form a &ggr;-turn, and amino acid residues in positions 3-4-5-1 to form a &bgr;-turn in combination with the &ggr;-turn; in which D-&agr;-amino acid residues are selected for A1, A3 and A5 and L-&agr;-amino acid residues are selected for A2 and A4 or wherein L-&agr;-amino acid residues are selected for A1, A3 and A5 and D-&agr;-amino acid residues are selected for A2 and A4; are provided.
    Type: Grant
    Filed: November 12, 1997
    Date of Patent: February 12, 2002
    Assignee: Takeda Chemical Industries, Inc.
    Inventors: Mitsuhiro Wakimasu, Hiroshi Inooka, Satoshi Endo, Takashi Kikuchi
  • Patent number: 5965526
    Abstract: Cyclic pentapeptides are disclosed having the following formula (I) --Cyclo(-A.sub.1 -A.sub.2 -A.sub.3 -A.sub.4 -A.sub.5 -)-- wherein A.sub.1, A.sub.2, A.sub.3, A.sub.4 and A.sub.5, are amino acid residues. The pentapeptide has amino acid residues in positions 1-2-3 to form a .gamma.-turn, and amino acid residues in positions 3-4-5-1 to form a .beta.-turn in combination with the .gamma.-turn. D-.alpha.-amino acid residues are selected for A.sub.1, A.sub.3, and A.sub.5 and L-.alpha.-amino acid residues are selected for A.sub.2 and A.sub.4. Compounds having .gamma.-turns and .beta.-turns can be synthesized, regardless of the kinds of amino acid residues, and it is possible to synthesize compounds in which desired amino acid residues are introduced into sites of .beta.-turn and .gamma.-turn based on their importance from the viewpoint of biological activity. The present invention is therefore available for design of compounds having biological activity.
    Type: Grant
    Filed: October 31, 1995
    Date of Patent: October 12, 1999
    Assignee: Takeda Chemical Industries, Inc.
    Inventors: Mitsuhiro Wakimasu, Hiroshi Inooka, Satoshi Endo, Takashi Kikuchi